Biotech beauty company Debut has announced the successful close of a $20 million funding round, aimed at accelerating its AI-driven platform for ingredient discovery and expanding its global formulation services. The round was led by Fine Structure Ventures, with participation from EDBI, Wealthberry, L’Oréal’s BOLD fund, GS Futures, Sandbox Industries, and Material Impact.

Founded by Dr. Joshua Britton, Debut specializes in developing bioidentical ingredients targeting the 14 hallmarks of aging, with a focus on skin longevity and performance-based formulations. The company’s proprietary platform screens over 50 billion molecules, enabling rapid identification of novel actives for use in skincare and personal care products.

“This funding allows us to scale our technology and bring biotech innovation to every beauty brand,” said Britton, CEO of Debut. The capital will support Debut’s expansion into Asian markets, beginning with Singapore, and bolster its contract manufacturing capabilities, allowing both indie and legacy brands to access biotech-powered formulations without heavy R&D investment.

Debut’s total funding now stands at $85 million, positioning it as a key player in the convergence of AI, biotechnology, and beauty innovation. The company’s in-house skincare brand, Deinde, launched in 2024, continues to outperform category benchmarks.